Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer.

B Shpitz1, E Klein, G Buklan

  • 1Department of Surgery, Sapir Medical Center, Meir General Hospital, Kfar Sava, Tel Aviv University Sackler School of Medicine, Israel. shpitza@post.tau.ac.il

Gut
|October 23, 2003

Related Experiment Videos

View abstract on PubMed

Summary

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Suppressive Effect Of Aspirin On Aberrant Crypt Foci In Patients With Colorectal Cancer.
    • This summary is machine-generated.

    Low-dose aspirin significantly reduced aberrant crypt foci (ACF) prevalence and density in colorectal cancer patients. This chemoprevention highlights aspirin's role in reducing colorectal cancer risk.

    Area of Science:

    • Gastroenterology
    • Oncology
    • Pharmacology

    Background:

    • Non-steroidal anti-inflammatory drugs, including aspirin, are known to decrease colorectal cancer (CRC) risk.
    • Animal studies indicate aspirin reduces aberrant crypt foci (ACF) density.
    • ACF are considered early precancerous lesions in the colon.

    Purpose of the Study:

    • To investigate the impact of chronic low-dose aspirin administration on the distribution and histological features of ACF in CRC patients.
    • To compare ACF patterns between CRC patients on aspirin and a control group.

    Main Methods:

    • A comparative study involving CRC patients treated with low-dose aspirin (n=59) and a control group (n=135).
    • Aberrant crypt foci (ACF) were identified in methylene blue-stained colonic mucosa.
    • ACF were microdissected, serially sectioned, and analyzed for distribution and characteristics.

    Main Results:

    • ACF prevalence decreased by 47% in the aspirin group compared to controls (36% vs. 75.8%).
    • A significant reduction in ACF prevalence was observed in distal colon samples (92.5% to 40%, p<0.0001).
    • Aspirin treatment led to a 64% and 82% reduction in ACF density in proximal and distal colon, respectively, with significant decreases in distal colon (p<0.01).
    • A 52% reduction in dysplastic ACF was noted in the aspirin group, though not statistically significant.

    Conclusions:

    • Low-dose aspirin demonstrates effective chemopreventive action against aberrant crypt foci (ACF) in humans.
    • Findings support aspirin's potential role in reducing colorectal cancer development by targeting precancerous lesions.

    Related Experiment Videos